-DOCSTART-	O

Title	O
:	O
Immunogenicity	O
and	O
reactogenicity	O
of	O
two	O
regimens	O
of	O
diphtheria	B-I
-	I-I
tetanus	I-I
-	I-I
acellular	I-I
pertussis	I-I
-	I-I
hepatitis	I-I
B	I-I
-	I-I
inactivated	I-I
polio	I-I
and	O
Haemophilus	B-I
influenzae	I-I
type	I-I
b	I-I
vaccines	I-I
administered	O
to	O
infants	B-P
primed	I-P
at	I-P
birth	I-P
with	I-P
hepatitis	I-P
B	I-P
vaccine	I-P
.	O

METHODS	O
:	O
One	O
-	O
half	O
of	O
the	O
150	O
healthy	O
,	O
full	O
-	O
term	O
infants	O
received	O
a	B-I
DTPa	I-I
HBV	I-I
-	I-I
IPV	I-I
-	I-I
Hib	I-I
vaccine	I-I
at	O
1	O
1	O
/	O
2	O
,	O
3	O
and	O
5	O
months	O
of	O
age	O
;	O
the	O
other	O
received	O
a	B-I
DTPa	I-I
-	I-I
IPV	I-I
-	I-I
Hib	I-I
vaccine	I-I
at	O
1	O
1	O
/	O
2	O
,	O
3	O
and	O
5	O
months	O
of	O
age	O
with	O
separate	B-I
HBV	I-I
vaccine	I-I
at	O
1	O
and	O
5	O
months	O
of	O
age	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
follow	O
-	O
up	O
of	O
a	O
randomized	O
trial	O
of	O
fludarabine	B-I
-	O
mitoxantrone	B-I
,	O
compared	O
with	O
cyclophosphamide	B-I
,	I-I
doxorubicin	I-I
,	I-I
vindesine	I-I
,	I-I
prednisone	I-I
(	I-I
CHVP	I-I
)	I-I
,	O
as	O
first	O
-	O
line	O
treatment	O
of	O
elderly	B-P
patients	I-P
with	I-P
advanced	I-P
,	I-P
low	I-P
-	I-P
grade	I-P
non	I-P
-	I-P
Hodgkin	I-P
'	I-P
s	I-P
lymphoma	I-P
before	O
the	O
era	O
of	O
monoclonal	O
antibodies	O
.	O

METHODS	O
:	O
End	O
points	O
were	O
remission	B-O
rates	I-O
[	O
overall	B-O
response	I-O
(	I-O
OR	I-O
)	I-O
and	O
complete	B-O
response	I-O
(	I-O
CR	I-O
)	I-O
]	O
,	O
failure	B-O
-	I-O
free	I-O
survival	I-O
(	I-O
FFS	I-O
)	I-O
,	O
survival	B-O
and	O
toxicity	B-O
.	O

One	B-P
hundred	I-P
and	I-P
fifty	I-P
-	I-P
five	I-P
patients	I-P
were	O
randomized	O
,	O
144	O
were	O
evaluable	O
for	O
safety	B-O
and	O
142	O
for	O
response	B-O
.	O

Each	O
treatment	O
arm	O
was	O
given	O
as	O
six	O
monthly	O
cycles	O
,	O
followed	O
by	O
three	O
bimonthly	O
cycles	O
.	O

FM	B-I
comprised	O
fludarabine	B-I
(	O
20	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
,	O
days	O
1	O
-	O
5	O
,	O
plus	O
mitoxantrone	B-I
(	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
,	O
day	O
1	O
.	O

CHVP	B-I
cycles	O
comprised	O
cyclophosphamide	B-I
(	O
750	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
infusion	O
)	O
,	O
doxorubicin	B-I
(	O
25	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
and	O
vindesine	B-I
(	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
i	O
.	O
v	O
.	O
)	O
on	O
day	O
1	O
,	O
and	O
prednisone	B-I
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
days	O
1	O
-	O
5	O
.	O

-DOCSTART-	O

Title	O
:	O
Reducing	O
blood	O
loss	O
at	O
open	O
myomectomy	O
using	O
triple	B-I
tourniquets	I-I
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomised	O
controlled	O
trial	O
.	O

Two	O
University	O
teaching	O
hospitals	O
.	O

Twenty	B-P
-	I-P
eight	I-P
patients	I-P
with	I-P
symptomatic	I-P
fibroids	I-P
and	I-P
uterine	I-P
sizes	I-P
ranging	I-P
from	I-P
14	I-P
to	I-P
24	I-P
weeks	I-P
of	I-P
gestation	I-P
undergoing	I-P
open	I-P
myomectomy	I-P
.	O

A	B-I
number	I-I
1	I-I
polyglactin	I-I
suture	I-I
was	O
tied	O
around	O
the	O
cervix	O
to	O
occlude	O
the	O
uterine	O
arteries	O
,	O
and	O
polythene	B-I
tourniquets	I-I
were	O
tied	O
around	O
the	O
infundibulopelvic	O
ligament	O
to	O
obstruct	O
the	O
ovarian	O
vessels	O
.	O

At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
the	O
ovarian	O
ties	O
were	O
released	O
but	O
the	O
uterine	O
artery	O
suture	O
remained	O
in	O
situ	O
.	O

Intra	B-O
-	I-O
operative	I-O
blood	I-O
loss	I-O
,	O
post	B-O
-	I-O
operative	I-O
blood	I-O
loss	I-O
,	O
blood	B-O
transfusion	I-O
rates	I-O
,	O
operative	B-O
morbidity	I-O
,	O
uterine	B-O
blood	I-O
flow	I-O
and	O
ovarian	B-O
function	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Controlled	O
clinical	O
trial	O
of	O
IV	B-I
cyclophosphamide	I-I
versus	O
IV	B-I
methylprednisolone	I-I
in	O
severe	O
neurological	O
manifestations	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
controlled	O
clinical	O
trial	O
at	O
two	O
tertiary	O
care	O
centres	O
of	O
patients	B-P
with	I-P
SLE	I-P
according	I-P
to	I-P
the	I-P
ACR	I-P
criteria	I-P
,	I-P
with	I-P
incident	I-P
(	I-P
no	I-P
more	I-P
than	I-P
15	I-P
days	I-P
)	I-P
onset	I-P
of	I-P
severe	I-P
NP	I-P
manifestations	I-P
such	I-P
as	I-P
seizures	I-P
,	I-P
optic	I-P
neuritis	I-P
,	I-P
peripheral	I-P
or	I-P
cranial	I-P
neuropathy	I-P
,	I-P
coma	I-P
,	I-P
brainstem	I-P
disease	I-P
,	I-P
or	I-P
transverse	I-P
myelitis	I-P
.	O

Induction	O
treatment	O
with	O
3	B-I
g	I-I
of	I-I
IV	I-I
methylprednisolone	I-I
(	I-I
MP	I-I
)	I-I
followed	O
by	O
either	O
IV	B-I
monthly	I-I
cyclophosphamide	I-I
(	I-I
Cy	I-I
)	I-I
versus	O
IV	B-I
MP	I-I
bimonthly	O
every	O
4	O
months	O
for	O
1	O
year	O
and	O
then	O
IV	B-I
Cy	I-I
or	O
IV	B-I
MP	I-I
every	O
3	O
months	O
for	O
another	O
year	O
.	O

The	O
primary	O
end	O
point	O
was	O
response	B-O
to	I-O
treatment	I-O
:	O
at	O
least	O
20	O
%	O
improvement	O
from	O
basal	O
conditions	O
on	O
clinical	B-O
,	O
laboratory	B-O
,	O
or	O
specific	B-O
neurological	I-O
testing	I-O
variables	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
nutritional	I-I
supplement	I-I
containing	O
vitamin	B-I
E	I-I
,	O
selenium	B-I
,	O
vitamin	B-I
c	I-I
and	O
coenzyme	B-I
Q10	I-I
on	O
serum	O
PSA	O
in	O
patients	B-P
with	I-P
hormonally	I-P
untreated	I-P
carcinoma	I-P
of	I-P
the	I-P
prostate	I-P
:	O
a	O
randomised	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
Eighty	B-P
patients	I-P
were	O
randomised	O
to	O
receive	O
a	B-I
daily	I-I
supplement	I-I
with	I-I
either	O
vitamin	B-I
E	O
,	O
selenium	B-I
,	O
vitamin	B-I
C	I-I
,	O
coenzyme	B-I
Q10	I-I
(	O
intervention	O
group	O
)	O
or	O
placebo	B-C
over	O
21	O
weeks	O
.	O

Serum	B-O
levels	I-O
of	I-O
PSA	I-O
were	O
assessed	O
at	O
baseline	O
(	O
-	O
2	O
,	O
-	O
1	O
,	O
0	O
weeks	O
)	O
and	O
after	O
6	O
,	O
13	O
,	O
19	O
,	O
20	O
and	O
21	O
weeks	O
.	O

Mean	O
changes	O
in	O
log	B-O
serum	I-O
level	I-O
of	I-O
PSA	I-O
,	O
testosterone	B-O
,	O
dihydrotestosterone	B-O
,	O
luteinizing	B-O
hormone	I-O
and	O
sex	B-O
hormone	I-O
binding	I-O
globulin	I-O
over	O
21	O
weeks	O
between	O
the	B-I
verum	I-I
and	O
the	B-C
placebo	I-C
group	O
were	O
compared	O
by	O
analysis	O
of	O
covariance	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
of	O
the	O
efficacy	O
of	O
heparinized	B-I
and	O
nonheparinized	B-I
solutions	I-I
for	O
maintenance	O
of	O
perioperative	O
radial	O
arterial	O
catheter	O
patency	O
and	O
subsequent	O
occlusion	O
.	O

METHODS	O
:	O
Two	B-P
-	I-P
hundred	I-P
patients	I-P
were	O
randomized	O
into	O
2	O
groups	O
to	O
receive	O
heparinized	B-I
(	O
group	O
H	O
,	O
n	O
=	O
100	O
)	O
or	O
nonheparinized	B-I
(	I-I
group	I-I
S	I-I
,	I-I
n	I-I
=	I-I
100	I-I
)	I-I
flush	I-I
solutions	I-I
.	O

Radial	B-O
and	O
ulnar	B-O
blood	I-O
flows	I-O
were	O
assessed	O
using	O
Doppler	B-O
probe	I-O
and	O
pulse	B-O
oximetry	I-O
before	O
,	O
just	O
after	O
,	O
and	O
24	O
h	O
after	O
decannulation	O
by	O
the	O
same	O
investigator	O
.	O

The	B-O
cannulation	I-O
site	I-O
was	O
examined	O
for	O
complications	B-O
such	O
as	O
hematoma	B-O
,	O
nerve	B-O
injury	I-O
,	O
and	O
infection	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Calcium	B-I
acetate	I-I
versus	O
calcium	B-I
carbonate	I-I
as	O
phosphate	O
binders	O
in	O
hemodialysis	B-P
patients	I-P
.	O

METHODS	O
:	O
All	O
patients	O
were	O
dialyzed	O
against	O
the	O
same	O
calcium	B-I
dialyzate	I-I
(	O
1	O
.	O
62	O
mmol	O
/	O
l	O
)	O
.	O

The	B-O
serum	I-O
analytical	I-O
tests	I-O
included	O
:	O
calcium	B-O
corrected	I-O
to	I-O
total	I-O
protein	I-O
,	O
P	B-O
,	O
PTH	B-O
(	B-O
intact	I-O
molecule	I-O
)	I-O
and	O
bicarbonate	B-O
.	O

The	O
study	O
was	O
divided	O
into	O
the	O
following	O
periods	O
:	O
P0	O
:	O
baseline	O
measurements	O
;	O
P1	O
:	O
washout	O
(	O
withdrawal	O
of	O
AH	O
for	O
15	O
days	O
)	O
;	O
P2	O
:	O
random	O
allocation	O
to	O
CA	B-I
and	O
CC	B-I
treatment	O
at	O
doses	O
equivalent	O
to	O
75	O
mEq	O
of	O
elemental	O
calcium	O
,	O
stratified	O
according	O
to	O
previous	O
doses	O
of	O
AH	O
(	O
2	O
months	O
)	O
;	O
P3	O
:	O
adjustment	O
of	O
doses	O
until	O
control	O
P	O
(	O
2	O
months	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Outcome	O
at	O
7	O
years	O
of	O
children	B-P
diagnosed	I-P
with	I-P
autism	I-P
at	I-P
age	I-P
2	I-P
:	O
predictive	O
validity	O
of	O
assessments	O
conducted	O
at	O
2	O
and	O
3	O
years	O
of	O
age	O
and	O
pattern	O
of	O
symptom	O
change	O
over	O
time	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
six	I-P
children	I-P
diagnosed	I-P
with	I-P
autism	I-P
at	I-P
age	I-P
2	I-P
were	O
re	O
-	O
assessed	O
at	O
ages	O
3	O
and	O
7	O
years	O
.	O

At	O
each	O
age	O
symptom	B-O
severity	I-O
,	O
cognitive	B-O
and	O
language	B-O
assessments	I-O
were	O
completed	O
.	O

-DOCSTART-	O

Title	O
:	O
Problem	O
-	O
based	O
learning	O
:	O
is	O
anatomy	O
a	O
casualty	O
?	O
.	O

METHODS	O
:	O
Testing	O
was	O
done	O
using	O
a	B-O
Questionnaire	I-O
in	I-O
a	I-O
"	I-O
True	I-O
/	I-O
False	I-O
"	I-O
format	I-O
.	O

There	O
were	O
80	O
students	O
in	O
each	O
group	O
.	O

There	O
was	O
no	O
penalty	O
for	O
an	O
incorrect	O
answer	O
.	O

The	O
test	O
was	O
performed	O
under	O
examination	O
conditions	O
.	O

Papers	O
were	O
marked	O
under	O
blind	O
conditions	O
.	O

Results	O
were	O
analysed	O
using	O
a	O
Student	O
'	O
s	O
t	O
test	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
home	B-I
strength	I-I
training	I-I
and	I-I
stretching	I-I
versus	O
stretching	B-C
alone	I-C
after	O
lumbar	O
disk	O
surgery	O
:	O
a	O
randomized	O
study	O
with	O
a	O
1	O
-	O
year	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Randomized	O
controlled	O
trial	O
.	O

Departments	O
of	O
physical	O
medicine	O
and	O
rehabilitation	O
and	O
orthopedics	O
at	O
a	O
Finnish	O
hospital	O
.	O

Patients	B-P
(	I-P
N=126	I-P
)	I-P
were	O
randomized	O
into	O
either	O
a	B-I
combined	I-I
strength	I-I
training	I-I
and	I-I
stretching	I-I
group	O
(	O
STG	O
,	O
n=65	O
)	O
or	O
a	O
control	O
group	O
(	O
CG	O
,	O
n=61	O
)	O
.	O

The	O
STG	O
was	O
instructed	O
to	O
perform	O
strength	O
training	O
and	O
both	O
the	O
STG	O
and	O
CG	O
were	O
instructed	O
in	O
the	O
same	O
stretching	O
and	O
stabilization	O
exercises	O
for	O
12	O
months	O
.	O

Pain	B-O
on	O
the	B-O
visual	I-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
,	O
the	B-O
Oswestry	I-O
and	I-O
the	I-O
Million	I-O
disability	I-O
indexes	I-O
,	O
isometric	B-O
and	O
dynamic	B-O
trunk	I-O
muscle	I-O
strength	I-O
,	O
mobility	B-O
in	I-O
the	I-O
lumbar	I-O
spine	I-O
,	O
and	O
straight	B-O
-	I-O
leg	I-O
raising	I-O
were	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Enhancement	O
of	O
blood	O
glucose	O
lowering	O
effect	O
of	O
a	B-I
sulfonylurea	I-I
when	O
coadministered	O
with	O
an	B-I
ACE	I-I
inhibitor	I-I
:	O
results	O
of	O
a	O
glucose	O
-	O
clamp	O
study	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
crossover	O
study	O
with	O
nine	B-P
healthy	I-P
normotensive	I-P
volunteers	I-P
(	I-P
age	I-P
27	I-P
+	I-P
/	I-P
-	I-P
3	I-P
y	I-P
,	I-P
BMI	I-P
23	I-P
.	I-P
3	I-P
+	I-P
/	I-P
-	I-P
2	I-P
.	I-P
0	I-P
kg	I-P
m	I-P
(	I-P
-	I-P
2	I-P
)	I-P
;	I-P
mean	I-P
+	I-P
/	I-P
-	I-P
SD	I-P
)	I-P
-	O
randomly	O
assigned	O
to	O
a	O
3	O
-	O
day	O
treatment	O
of	O
either	O
5	B-I
mg	I-I
enalapril	I-I
or	O
placebo	B-C
.	O

In	O
the	O
morning	O
of	O
the	O
fourth	O
day	O
,	O
volunteers	O
orally	O
received	O
3	B-I
.	I-I
5	I-I
mg	I-I
glibenclamide	I-I
together	O
with	O
either	O
10	B-I
mg	I-I
enalapril	I-I
or	O
placebo	B-C
.	O

Blood	B-O
glucose	I-O
levels	I-O
of	O
volunteers	O
were	O
allowed	O
to	O
fall	O
by	O
10	O
%	O
from	O
fasting	O
levels	O
and	O
were	O
kept	O
constant	O
thereafter	O
by	O
employing	O
a	B-O
Biostator	I-O
-	I-O
based	I-O
euglycemic	I-O
glucose	I-O
clamp	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
of	O
urinary	O
and	O
sexual	O
outcomes	O
in	O
women	O
experiencing	O
vaginal	B-I
and	O
Caesarean	B-I
births	I-I
.	O

METHODS	O
:	O
We	O
performed	O
a	O
cohort	O
analysis	O
of	O
data	O
from	O
a	O
randomized	O
controlled	O
trial	O
of	O
episiotomy	O
conducted	O
in	O
3	O
Montreal	O
hospitals	O
in	O
1990	O
-	O
1991	O
.	O

Of	O
the	O
999	B-P
trial	I-P
participants	I-P
for	I-P
whom	I-P
follow	I-P
-	I-P
up	I-P
data	I-P
were	I-P
available	I-P
,	O
135	O
delivered	O
by	O
Caesarean	B-I
section	I-I
(	I-I
CS	I-I
)	I-I
,	O
and	O
864	O
had	O
a	B-I
vaginal	I-I
birth	I-I
(	I-I
VB	I-I
)	I-I
.	O

After	O
stratifying	O
for	O
parity	O
,	O
we	O
compared	O
rates	B-O
of	I-O
urinary	I-O
incontinence	I-O
(	I-O
UI	I-O
)	I-O
and	O
sexual	B-O
functioning	I-O
at	O
3	O
months	O
postpartum	O
in	O
women	O
who	O
had	O
a	B-I
VB	I-I
with	O
the	O
rates	O
in	O
women	O
who	O
had	O
a	B-I
CS	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
,	O
tolerability	O
,	O
and	O
changes	O
in	O
amyloid	O
beta	O
concentrations	O
after	O
administration	O
of	O
a	B-I
gamma	I-I
-	I-I
secretase	I-I
inhibitor	I-I
in	O
volunteers	O
.	O

METHODS	O
:	O
Volunteer	B-P
subjects	I-P
(	I-P
N	I-P
=	I-P
37	I-P
)	I-P
were	O
studied	O
using	O
doses	B-I
from	I-I
5	I-I
to	I-I
50	I-I
mg	I-I
/	I-I
day	I-I
given	O
for	O
14	O
days	O
.	O

Plasma	B-O
and	O
CSF	B-O
concentrations	I-O
of	I-O
LY450139	I-O
,	O
Abeta	B-O
(	I-O
1	I-O
-	I-O
40	I-O
)	I-O
and	O
Abeta	B-O
(	I-O
1	I-O
-	I-O
X	I-O
)	I-O
(	B-O
"	I-O
Abeta	I-O
(	I-O
total	I-O
)	I-O
"	I-O
)	I-O
were	O
determined	O
,	O
and	O
safety	B-O
and	O
tolerability	B-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
assessment	O
of	O
erythema	O
and	O
thickness	O
on	O
burn	O
related	O
scars	O
during	O
pressure	B-I
garment	I-I
therapy	I-I
as	O
a	O
preventive	O
measure	O
for	O
hypertrophic	O
scarring	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
prospective	O
trial	O
in	O
which	O
76	B-P
burn	I-P
scars	I-P
in	I-P
60	I-P
patients	I-P
were	O
objectively	O
assessed	O
with	O
the	B-O
Minolta	I-O
Chromameter	I-O
CR	I-O
-	I-O
300	I-O
for	O
erythema	B-O
and	O
with	O
the	B-O
Dermascan	I-O
C	I-O
for	O
thickness	B-O
of	I-O
the	I-O
scar	I-O
over	O
a	O
period	O
of	O
3	O
months	O
.	O

Each	O
patient	O
was	O
randomly	O
assigned	O
to	O
a	B-I
"	I-I
normal	I-I
"	I-I
or	O
"	O
lower	B-I
"	I-I
compression	I-I
class	I-I
treatment	I-I
,	O
with	O
respectively	O
mean	O
values	O
of	O
15	O
and	O
10	O
mmHg	O
pressure	O
after	O
wearing	O
the	O
garment	O
for	O
1	O
month	O
.	O

Measurements	O
for	O
both	O
parameters	O
were	O
taken	O
at	O
0	O
,	O
1	O
,	O
2	O
and	O
3	O
months	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Determinants	O
of	O
the	O
effect	O
of	O
estrogen	B-I
on	O
the	O
progression	O
of	O
subclinical	O
atherosclerosis	O
:	O
Estrogen	B-I
in	O
the	O
Prevention	O
of	O
Atherosclerosis	O
Trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
center	O
trial	O
enrolling	O
222	B-P
postmenopausal	I-P
women	I-P
45	I-P
years	I-P
and	I-P
older	I-P
without	I-P
cardiovascular	I-P
disease	I-P
and	I-P
with	I-P
low	I-P
-	I-P
density	I-P
lipoprotein	I-P
(	I-P
LDL	I-P
)	I-P
cholesterol	I-P
levels	I-P
of	I-P
3	I-P
.	I-P
37	I-P
mmol	I-P
/	I-P
L	I-P
or	I-P
greater	I-P
(	I-P
>	I-P
or	I-P
=	I-P
130	I-P
mg	I-P
/	I-P
dL	I-P
)	I-P
.	O

Intervention	O
was	O
unopposed	B-I
micronized	I-I
17beta	I-I
-	I-I
estradiol	I-I
versus	O
placebo	B-C
.	O

Measurements	O
were	O
made	O
using	O
high	B-O
-	I-O
resolution	I-O
B	I-O
-	I-O
mode	I-O
ultrasonography	I-O
to	O
measure	O
carotid	B-O
artery	I-O
IMT	I-O
at	O
baseline	O
and	O
every	O
6	O
months	O
on	O
-	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Reactivation	O
of	O
unstable	O
angina	O
after	O
the	B-I
discontinuation	I-I
of	I-I
heparin	I-I
.	O

METHODS	O
:	O
The	O
study	O
population	O
included	O
403	B-P
of	I-P
the	I-P
original	I-P
479	I-P
patients	I-P
in	I-P
the	I-P
trial	I-P
who	I-P
had	I-P
completed	I-P
six	I-P
days	I-P
of	I-P
blinded	I-P
therapy	I-P
without	I-P
refractory	I-P
angina	I-P
or	I-P
myocardial	I-P
infarction	I-P
.	O

After	O
the	B-I
discontinuation	I-I
of	I-I
therapy	I-I
,	O
clinical	B-O
events	I-O
,	O
including	O
reactivation	B-O
of	I-O
unstable	I-O
angina	I-O
and	O
myocardial	B-O
infarction	I-O
occurring	O
within	O
96	O
hours	O
after	O
hospitalization	O
,	O
were	O
closely	O
monitored	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
immunogenicity	O
of	O
an	B-I
oral	I-I
,	O
inactivated	B-I
,	O
whole	B-I
-	I-I
cell	I-I
vaccine	I-I
for	I-I
Shigella	I-I
sonnei	I-I
:	O
preclinical	O
studies	O
and	O
a	O
Phase	O
I	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
Phase	O
I	O
study	O
,	O
10	B-I
evaluable	I-I
subjects	I-I
received	O
either	O
three	B-I
doses	I-I
of	I-I
SsWC	I-I
on	O
Days	O
0	O
,	O
14	O
,	O
and	O
28	O
(	O
N	O
=	O
3	O
)	O
;	O
five	B-I
doses	I-I
of	I-I
SsWC	I-I
on	O
Days	O
0	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
28	O
(	O
N	O
=	O
4	O
)	O
;	O
or	O
placebo	B-C
(	O
N	O
=	O
3	O
)	O
.	O

Each	O
dose	O
contained	O
2	B-I
.	I-I
0	I-I
x	I-I
10	I-I
(	I-I
10	I-I
)	I-I
inactivated	I-I
cells	I-I
.	O

Serum	B-O
and	O
fecal	B-O
antibodies	I-O
against	I-O
SsWC	I-O
,	O
LPS	B-O
,	O
and	O
IpaC	B-O
were	O
measured	O
by	O
ELISA	B-O
.	O

A	O
>	O
or	O
=	O
4	O
-	O
fold	O
increase	O
in	O
titer	O
was	O
considered	O
significant	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
exercise	B-I
,	O
training	B-I
,	O
and	O
glycogen	B-I
availability	I-I
on	O
IL	O
-	O
6	O
receptor	O
expression	O
in	O
human	O
skeletal	O
muscle	O
.	O

METHODS	O
:	O
Human	B-P
subjects	I-P
performed	O
either	O
10	B-I
wk	I-I
of	I-I
training	I-I
with	I-I
an	I-I
acute	I-I
exercise	I-I
bout	O
before	O
and	O
after	O
the	O
training	O
period	O
,	O
or	O
a	B-I
low	I-I
-	I-I
glycogen	I-I
vs	O
.	O
normal	B-I
-	I-I
glycogen	I-I
acute	I-I
exercise	I-I
trial	I-I
.	O

The	B-O
IL	I-O
-	I-O
6R	I-O
mRNA	I-O
response	I-O
was	O
evaluated	O
in	O
both	O
trials	O
.	O

-DOCSTART-	O

Title	O
:	O
Double	O
blind	O
,	O
placebo	O
controlled	O
study	O
of	O
metronidazole	B-I
as	O
a	O
disease	O
modifying	O
agent	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

METHODS	O
:	O
Fifty	B-P
patients	I-P
with	I-P
active	I-P
rheumatoid	I-P
arthritis	I-P
were	O
randomly	O
allocated	O
to	O
receive	O
active	O
drug	O
(	O
n	O
=	O
24	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
26	O
)	O
and	O
reviewed	O
at	O
weeks	O
0	O
,	O
1	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
and	O
24	O
.	O

Detailed	O
assessment	O
of	O
drug	B-O
safety	I-O
,	O
biochemical	B-O
and	O
haematological	B-O
parameters	I-O
,	O
and	O
efficacy	B-O
was	O
made	O
at	O
these	O
dates	O
.	O

Dose	O
regimen	O
was	O
400	O
mg	O
twice	O
daily	O
from	O
weeks	O
0	O
to	O
eight	O
,	O
increasing	O
to	O
400	O
mg	O
three	O
times	O
a	O
day	O
from	O
weeks	O
nine	O
to	O
24	O
provided	O
that	O
no	O
adverse	B-O
effects	I-O
were	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Usage	O
of	O
titanoreine	B-I
after	O
procedure	O
for	O
prolapse	O
and	O
hemorrhoids	O
]	O
.	O

METHODS	O
:	O
From	O
November	O
2002	O
to	O
July	O
2003	O
,	O
80	B-P
patients	I-P
who	I-P
received	I-P
PPH	I-P
were	O
randomly	O
divided	O
in	O
to	O
titanoreine	B-I
group	O
(	O
n=42	O
)	O
and	O
control	O
group	O
without	B-C
titanoreine	I-C
(	O
n=38	O
)	O
.	O

Symptom	B-O
relief	I-O
was	O
recorded	O
24	O
hours	O
,	O
6	O
days	O
and	O
12	O
days	O
after	O
PPH	O
,	O
urine	B-O
retention	I-O
24h	O
after	O
PPH	O
,	O
first	B-O
stool	I-O
time	I-O
,	O
wound	B-O
healing	I-O
time	I-O
,	O
mean	B-O
hospital	I-O
stay	I-O
were	O
also	O
recorded	O
.	O

-DOCSTART-	O

Title	O
:	O
Family	B-I
education	I-I
for	O
people	B-P
with	I-P
schizophrenia	I-P
in	I-P
Beijing	I-P
,	I-P
China	I-P
:	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomised	O
controlled	O
trial	O
was	O
conducted	O
in	O
a	O
large	O
hospital	O
with	O
a	O
was	O
conducted	O
in	O
a	O
large	O
hospital	O
with	O
a	B-P
sample	I-P
of	I-P
101	I-P
patients	I-P
with	I-P
schizophrenia	I-P
and	I-P
their	I-P
families	I-P
.	O

Data	O
were	O
collected	O
at	O
admission	O
and	O
at	O
discharge	O
,	O
and	O
then	O
at	O
3	O
and	O
9	O
months	O
after	O
discharge	O
.	O

The	O
intervention	O
group	O
received	O
family	B-I
education	I-I
,	O
and	O
data	O
on	O
their	O
knowledge	B-O
about	I-O
schizophrenia	I-O
,	O
symptoms	B-O
,	O
functioning	B-O
,	O
psychosocial	B-O
behaviour	I-O
,	O
relapse	B-O
and	O
medication	B-O
adherence	I-O
were	O
collected	O
and	O
compared	O
with	O
the	O
control	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Single	O
-	O
use	O
plaque	O
removal	O
efficacy	O
of	O
three	B-I
power	I-I
toothbrushes	I-I
.	O

METHODS	O
:	O
After	O
refraining	O
from	O
all	O
oral	O
hygiene	O
procedures	O
for	O
23	O
-	O
25	O
hours	O
,	O
subjects	B-P
received	I-P
an	I-P
oral	I-P
tissue	I-P
examination	I-P
and	I-P
those	I-P
with	I-P
pre	I-P
-	I-P
brushing	I-P
whole	I-P
mouth	I-P
mean	I-P
plaque	I-P
scores	I-P
>	I-P
or	I-P
=	I-P
0	I-P
.	I-P
6	I-P
based	I-P
on	I-P
the	I-P
Rustogi	I-P
et	I-P
al	I-P
.	I-P

Modified	I-P
Navy	I-P
Plaque	I-P
Index	I-P
were	O
randomly	O
assigned	O
to	O
treatment	O
sequence	O
.	O

After	O
brushing	O
with	O
the	B-I
assigned	I-I
toothbrush	I-I
and	O
a	O
commercially	O
available	O
dentifrice	O
for	O
2	O
minutes	O
,	O
oral	B-O
tissues	I-O
were	O
then	O
re	O
-	O
examined	O
and	O
post	B-O
-	I-O
brushing	I-O
plaque	I-O
scores	I-O
recorded	O
.	O

Following	O
a	O
brief	O
washout	O
period	O
between	O
two	O
additional	O
visits	O
,	O
the	O
above	O
procedures	O
were	O
repeated	O
with	O
the	O
two	O
alternate	O
toothbrushes	O
.	O

One	O
examiner	O
,	O
blinded	O
to	O
the	O
treatment	O
sequence	O
,	O
performed	O
all	O
clinical	O
measurements	O
.	O

-DOCSTART-	O

Title	O
:	O
Intensive	B-I
behavioral	I-I
treatment	I-I
for	O
children	B-P
with	I-P
autism	I-P
:	O
four	O
-	O
year	O
outcome	O
and	O
predictors	O
.	O

METHODS	O
:	O
Twenty	B-P
-	I-P
four	I-P
children	I-P
with	I-P
autism	I-P
were	O
randomly	O
assigned	O
to	O
a	B-I
clinic	I-I
-	I-I
directed	I-I
group	O
,	O
replicating	O
the	O
parameters	O
of	O
the	B-I
early	I-I
intensive	I-I
behavioral	I-I
treatment	I-I
developed	O
at	O
UCLA	O
,	O
or	O
to	O
a	O
parent	O
-	O
directed	O
group	O
that	O
received	O
intensive	B-I
hours	I-I
but	I-I
less	I-I
supervision	I-I
by	I-I
equally	I-I
well	I-I
-	I-I
trained	I-I
supervisors	I-I
.	O

Outcome	O
after	O
4	O
years	O
of	O
treatment	O
,	O
including	O
cognitive	B-O
,	O
language	B-O
,	O
adaptive	B-O
,	O
social	B-O
,	O
and	O
academic	B-O
measures	I-O
,	O
was	O
similar	O
for	O
both	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
trials	O
of	O
intrasplenic	B-I
arterial	I-I
infusion	I-I
of	I-I
interleukin	I-I
-	I-I
2	I-I
(	I-I
IS	I-I
-	I-I
IL	I-I
-	I-I
2	I-I
)	I-I
to	O
patients	B-P
with	I-P
advanced	I-P
cancer	I-P
.	O

METHODS	O
:	O
Eighteen	B-P
patients	I-P
of	I-P
colorectal	I-P
cancer	I-P
with	I-P
metastases	I-P
to	I-P
the	I-P
liver	I-P
or	I-P
lung	I-P
or	I-P
of	I-P
unresectable	I-P
hepatoma	I-P
received	O
a	B-I
24	I-I
hour	I-I
continuous	I-I
infusion	I-I
with	I-I
low	I-I
dose	I-I
recombinant	I-I
of	I-I
IL	I-I
-	I-I
2	I-I
(	O
mainly	O
8	O
x	O
10	O
(	O
5	O
)	O
JRU	O
/	O
day	O
)	O
for	O
25	O
-	O
40	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
effects	O
of	O
risperidone	B-I
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
placebo	O
discontinuation	O
study	O
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
six	I-P
children	I-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
5	I-P
-	I-P
17	I-P
years	I-P
old	I-P
)	I-P
accompanied	I-P
by	I-P
severe	I-P
tantrums	I-P
,	I-P
aggression	I-P
,	I-P
or	I-P
self	I-P
-	I-P
injurious	I-P
behavior	I-P
,	O
started	O
8	B-I
-	I-I
week	I-I
open	I-I
-	I-I
label	I-I
treatment	I-I
with	I-I
risperidone	I-I
.	O

Responders	O
(	O
n	O
=	O
26	O
)	O
continued	O
treatment	O
for	O
another	O
16	O
weeks	O
,	O
followed	O
by	O
a	O
double	O
-	O
blind	O
discontinuation	O
(	O
n	O
=	O
24	O
;	O
two	O
patients	O
discontinued	O
treatment	O
because	O
of	O
weight	O
gain	O
)	O
consisting	O
of	O
either	B-I
3	I-I
weeks	I-I
of	I-I
taper	I-I
and	O
5	B-C
weeks	I-C
of	I-C
placebo	I-C
only	I-C
or	O
continuing	B-I
use	I-I
of	I-I
risperidone	I-I
.	O

Relapse	B-O
was	O
defined	O
as	O
a	B-O
significant	I-O
deterioration	I-O
of	I-O
symptoms	I-O
based	I-O
on	I-O
clinical	I-O
judgment	I-O
and	O
a	B-O
parent	I-O
questionnaire	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
antihypertensives	B-I
after	O
coronary	O
artery	O
surgery	O
.	O

METHODS	O
:	O
Diltiazem	B-I
was	O
administered	O
as	O
an	O
intravenous	O
bolus	O
of	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
within	O
5	O
min	O
,	O
followed	O
by	O
infusion	O
of	O
0	O
.	O
1	O
-	O
0	O
.	O

8	O
mg	O
.	O
kg	O
-	O
1	O
.	O
h	O
-	O
1	O
in	O
group	O
1	O
.	O

Nitroglycerin	B-I
was	O
infused	O
at	O
a	O
rate	O
of	O
1	O
-	O
3	O
microg	O
.	O
kg	O
.	O
h	O
-	O
1	O
in	O
group	O
2	O
,	O
and	O
sodium	B-I
nitroprusside	I-I
was	O
given	O
at	O
a	O
rate	O
of	O
1	O
-	O
3	O
microg	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
in	O
group	O
3	O
.	O

Hemodynamic	B-O
measurements	I-O
were	O
carried	O
out	O
before	O
infusion	O
(	O
T1	O
)	O
and	O
at	O
30	O
min	O
(	O
T2	O
)	O
,	O
2	O
h	O
(	O
T3	O
)	O
,	O
and	O
12	O
h	O
(	O
T4	O
)	O
after	O
initiation	O
of	O
treatment	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

-DOCSTART-	O

Title	O
:	O
Phytase	B-I
and	O
1alpha	B-I
-	I-I
hydroxycholecalciferol	I-I
supplementation	I-I
of	O
broiler	B-P
chickens	I-P
during	O
the	O
starting	O
and	O
growing	O
/	O
finishing	O
phases	O
.	O

METHODS	O
:	O
In	O
both	O
experiments	O
,	O
at	O
least	O
4	O
replicates	O
per	O
treatment	O
(	O
50	O
chicks	O
per	O
replicate	O
)	O
were	O
used	O
.	O

Corn	B-I
-	I-I
soybean	I-I
-	I-I
meal	I-I
-	O
and	O
soybean	B-I
-	I-I
oil	I-I
-	I-I
based	I-I
diets	I-I
were	O
fed	O
and	O
birds	O
were	O
raised	O
in	O
a	O
house	O
impervious	O
to	O
ultraviolet	O
light	O
.	O

During	O
the	O
starter	O
phase	O
(	O
ST	O
)	O
,	O
from	O
0	O
to	O
18	O
d	O
,	O
chicks	O
were	O
fed	O
a	O
23	O
%	O
CP	O
diet	O
containing	O
0	O
.	O
60	O
%	O
Ca	O
and	O
0	O
.	O
47	O
%	O
total	O
P	O
(	O
tP	O
)	O
.	O

During	O
the	O
grower	O
/	O
finisher	O
phase	O
(	O
GF	O
)	O
,	O
from	O
19	O
to	O
35	O
d	O
,	O
birds	O
were	O
fed	O
a	O
19	O
%	O
CP	O
diet	O
containing	O
0	O
.	O
30	O
%	O
Ca	O
and	O
0	O
.	O
37	O
%	O
tP	O
.	O

A	B-I
combination	I-I
of	I-I
1	I-I
,	I-I
000	I-I
phytase	I-I
units	I-I
/	I-I
kg	I-I
of	I-I
Natuphos	I-I
phytase	I-I
and	O
5	B-I
microg	I-I
/	I-I
kg	I-I
of	I-I
1alpha	I-I
-	I-I
OHD3	I-I
(	I-I
P	I-I
+	I-I
1A	I-I
)	I-I
was	O
supplemented	O
to	O
some	O
of	O
the	O
feed	O
during	O
the	O
ST	O
and	O
GF	O
.	O

Diets	O
containing	O
adequate	O
Ca	O
and	O
P	O
were	O
also	O
fed	O
during	O
the	O
ST	O
(	O
0	O
.	O
90	O
%	O
Ca	O
,	O
0	O
.	O
68	O
%	O
tP	O
)	O
and	O
GF	O
(	O
0	O
.	O
80	O
%	O
Ca	O
,	O
0	O
.	O
67	O
%	O
tP	O
)	O
.	O

Performance	B-O
characteristics	I-O
and	O
the	B-O
incidence	I-O
of	I-O
rickets	I-O
and	I-O
tibial	I-O
dyschondroplasia	I-O
were	O
measured	O
at	O
18	O
and	O
35	O
d	O
.	O

In	O
experiment	O
1	O
,	O
unsupplemented	O
chicks	O
performed	O
well	O
but	O
had	O
considerable	O
leg	O
problems	O
.	O

-DOCSTART-	O

Title	O
:	O
Project	O
Towards	O
No	O
Drug	O
Abuse	O
:	O
long	O
-	O
term	O
substance	O
use	O
outcomes	O
evaluation	O
.	O

METHODS	O
:	O
The	O
effects	O
of	O
a	B-I
9	I-I
-	I-I
session	I-I
health	I-I
motivation	I-I
-	I-I
-	I-I
social	I-I
skills	I-I
-	I-I
-	I-I
decision	I-I
-	I-I
making	I-I
curriculum	I-I
were	O
evaluated	O
.	O

Twenty	O
-	O
one	O
schools	O
recruited	O
were	O
randomly	O
assigned	O
to	O
standard	B-C
care	I-C
(	O
control	O
)	O
,	O
classroom	B-I
only	I-I
,	O
or	O
a	B-I
classroom	I-I
plus	O
semester	B-I
-	I-I
long	I-I
school	I-I
-	I-I
as	I-I
-	I-I
community	I-I
component	I-I
.	O

Last	B-O
30	I-O
-	I-O
day	I-O
use	I-O
of	I-O
cigarettes	I-O
,	O
alcohol	B-O
,	O
marijuana	B-O
,	O
and	O
hard	B-O
drugs	I-O
were	O
assessed	O
at	O
three	O
time	O
intervals	O
:	O
short	O
-	O
term	O
(	O
year	O
1	O
)	O
,	O
middle	O
-	O
term	O
(	O
years	O
2	O
or	O
3	O
)	O
,	O
and	O
long	O
-	O
term	O
(	O
years	O
4	O
or	O
5	O
)	O
.	O

Multilevel	O
random	O
coefficients	O
modeling	O
were	O
employed	O
to	O
estimate	O
the	O
adjusted	O
levels	O
of	O
substance	O
use	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
remifentanil	B-I
with	O
fentanyl	B-I
for	O
deep	O
sedation	O
in	O
oral	O
surgery	O
.	O

METHODS	O
:	O
This	O
investigation	O
was	O
designed	O
as	O
a	O
randomized	O
,	O
prospective	O
,	O
single	O
-	O
blinded	O
controlled	O
study	O
.	O

Group	O
1	O
,	O
the	O
control	O
,	O
received	O
midazolam	B-C
0	O
.	O
03	O
mg	O
/	O
kg	O
,	O
fentanyl	B-C
1	O
microg	O
/	O
kg	O
,	O
and	O
propofol	B-C
initially	O
at	O
140	O
microg	O
/	O
kg	O
/	O
min	O
.	O

Group	O
2	O
received	O
midazolam	B-I
0	O
.	O
03	O
mg	O
/	O
kg	O
,	O
remifentanil	B-I
:	O
propofol	B-I
(	O
1	O
:	O
500	O
)	O
given	O
at	O
an	O
initial	O
propofol	O
infusion	O
rate	O
of	O
40	O
microg	O
/	O
kg	O
/	O
min	O
.	O

Outcome	O
measures	O
included	O
time	B-O
to	I-O
response	I-O
to	I-O
verbal	I-O
command	I-O
,	O
Aldrete	B-O
score	I-O
=	I-O
9	I-O
,	O
Postanesthesia	B-O
Discharge	I-O
Scoring	I-O
System	I-O
=	I-O
7	I-O
,	O
and	O
assessment	O
by	O
the	B-O
Digit	I-O
Symbol	I-O
Substitution	I-O
Test	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
influence	O
of	O
rTMS	B-I
over	O
the	O
left	O
dorsolateral	O
prefrontal	O
cortex	O
on	O
Stroop	O
task	O
performance	O
.	O

METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
the	B-I
influence	I-I
of	I-I
high	I-I
-	I-I
frequency	I-I
rTMS	I-I
over	O
the	O
left	O
DLPFC	O
on	O
Stroop	B-O
task	I-O
performance	I-O
in	O
healthy	B-P
female	I-P
volunteers	I-P
was	O
investigated	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Comparison	O
of	O
the	O
efficacy	O
/	O
tolerability	O
ratio	O
of	O
cibenzoline	B-I
and	O
propafenone	B-I
in	O
the	O
treatment	O
of	O
ventricular	O
arrhythmia	O
]	O
.	O

METHODS	O
:	O
After	O
a	O
therapeutic	O
wash	O
-	O
out	O
period	O
corresponding	O
to	O
5	O
times	O
the	O
half	O
-	O
life	O
of	O
previous	O
anti	O
-	O
arrhythmic	O
drugs	O
,	O
patients	B-P
with	I-P
more	I-P
than	I-P
100	I-P
premature	I-P
ventricular	I-P
contractions	I-P
(	I-P
PVC	I-P
)	I-P
per	I-P
hour	I-P
in	I-P
two	I-P
24	I-P
hour	I-P
Holter	I-P
records	I-P
obtained	I-P
at	I-P
an	I-P
interval	I-P
of	I-P
7	I-P
days	I-P
were	O
treated	O
in	O
succession	O
and	O
after	O
randomised	O
by	O
C	B-I
(	O
390	O
mg	O
/	O
day	O
in	O
3	O
divided	O
doses	O
)	O
and	O
P	B-I
(	O
900	O
mg	O
/	O
day	O
in	O
3	O
divided	O
doses	O
)	O
for	O
a	O
period	O
of	O
two	O
weeks	O
,	O
each	O
active	O
sequence	O
being	O
followed	O
by	O
a	O
two	O
week	O
wash	O
-	O
out	O
period	O
.	O

Efficacy	B-O
(	O
based	O
upon	O
the	O
decrease	O
in	O
PVC	B-O
/	I-O
hour	I-O
in	O
a	O
24	O
hour	O
Holter	O
)	O
and	O
tolerability	B-O
were	O
evaluated	O
at	O
the	O
end	O
of	O
each	O
sequence	O
,	O
with	O
samples	O
drawn	O
at	O
the	O
same	O
times	O
for	O
assay	O
of	O
the	O
study	O
drugs	O
.	O

-DOCSTART-	O

Title	O
:	O
Sham	B-I
device	I-I
v	O
inert	B-I
pill	I-I
:	O
randomised	O
controlled	O
trial	O
of	O
two	O
placebo	O
treatments	O
.	O

METHODS	O
:	O
A	O
single	O
blind	O
randomised	O
controlled	O
trial	O
created	O
from	O
the	O
two	O
week	O
placebo	O
run	O
-	O
in	O
periods	O
for	O
two	O
nested	O
trials	O
that	O
compared	O
acupuncture	O
and	O
amitriptyline	O
with	O
their	O
respective	O
placebo	O
controls	O
.	O

Comparison	O
of	O
participants	O
who	O
remained	O
on	O
placebo	B-C
continued	O
beyond	O
the	O
run	O
-	O
in	O
period	O
to	O
the	O
end	O
of	O
the	O
study	O
.	O

Academic	O
medical	O
centre	O
.	O

270	B-P
adults	I-P
with	I-P
arm	I-P
pain	I-P
due	I-P
to	I-P
repetitive	I-P
use	I-P
that	I-P
had	I-P
lasted	I-P
at	I-P
least	I-P
three	I-P
months	I-P
despite	I-P
treatment	I-P
and	I-P
who	I-P
scored	I-P
>	I-P
or	I-P
=3	I-P
on	I-P
a	I-P
10	I-P
point	I-P
pain	I-P
scale	I-P
.	O

Acupuncture	B-I
with	I-I
sham	I-I
device	I-I
twice	O
a	O
week	O
for	O
six	O
weeks	O
or	O
placebo	B-C
pill	I-C
once	O
a	O
day	O
for	O
eight	O
weeks	O
.	O

Arm	B-O
pain	I-O
measured	O
on	O
a	B-O
10	I-O
point	I-O
pain	I-O
scale	I-O
.	O

Secondary	O
outcomes	O
were	O
symptoms	B-O
measured	O
by	O
the	B-O
Levine	I-O
symptom	I-O
severity	I-O
scale	I-O
,	O
function	B-O
measured	O
by	O
Pransky	B-O
'	I-O
s	I-O
upper	I-O
extremity	I-O
function	I-O
scale	I-O
,	O
and	O
grip	B-O
strength	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Perceptual	O
wind	O
-	O
up	O
in	O
the	O
human	O
oesophagus	O
is	O
enhanced	O
by	O
central	B-I
sensitisation	I-I
.	O

METHODS	O
:	O
In	B-P
eight	I-P
healthy	I-P
volunteers	I-P
(	I-P
seven	I-P
males	I-P
;	I-P
mean	I-P
age	I-P
32	I-P
years	I-P
)	I-P
,	O
perception	B-O
at	I-O
pain	I-O
threshold	I-O
to	O
a	B-I
train	I-I
of	I-I
20	I-I
electrical	I-I
stimuli	I-I
applied	O
to	O
the	O
hand	O
and	O
upper	O
oesophagus	O
(	O
UO	O
)	O
at	O
either	O
0	O
.	O
1	O
Hz	O
(	O
control	O
)	O
or	O
2	O
Hz	O
was	O
determined	O
before	O
and	O
one	O
hour	O
after	O
a	O
30	O
minute	O
lower	O
oesophageal	O
acid	O
infusion	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
prostaglandin	B-I
E1	I-I
for	O
prevention	O
of	O
respiratory	O
failure	O
in	O
high	B-P
risk	I-P
trauma	I-P
patients	I-P
:	O
a	O
prospective	O
clinical	O
trial	O
and	O
correlation	O
with	O
plasma	O
suppressive	O
factors	O
for	O
neutrophil	O
activation	O
.	O

METHODS	O
:	O
Secondary	O
assessments	O
examined	O
the	O
effects	O
of	O
the	B-I
PGE1	I-I
infusion	I-I
on	O
plasma	B-O
mediated	I-O
suppression	I-O
of	I-O
PMN	I-O
superoxide	I-O
production	I-O
and	O
loss	B-O
of	I-O
PMN	I-O
granule	I-O
enzyme	I-O
content	I-O
.	O

METHODS	O
:	O
The	B-O
suppressive	I-O
activity	I-O
of	I-O
the	I-O
patient	I-O
plasma	I-O
was	O
assayed	O
by	O
measurement	O
of	O
normal	B-O
PMN	I-O
superoxide	I-O
production	I-O
relative	I-O
to	I-O
normal	I-O
control	I-O
plasma	I-O
(	O
ratio	B-O
P	I-O
:	I-O
C	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Endurance	B-I
training	I-I
has	O
little	O
effect	O
on	O
active	O
muscle	O
free	O
fatty	O
acid	O
,	O
lipoprotein	O
cholesterol	O
,	O
or	O
triglyceride	O
net	O
balances	O
.	O

METHODS	O
:	O
Eight	B-P
sedentary	I-P
men	I-P
(	I-P
26	I-P
+	I-P
/	I-P
-	I-P
1	I-P
yr	I-P
,	I-P
77	I-P
.	I-P
4	I-P
+	I-P
/	I-P
-	I-P
3	I-P
.	I-P
7	I-P
kg	I-P
)	I-P
were	O
studied	O
in	O
the	O
postprandial	O
state	O
during	O
90	B-I
min	I-I
of	I-I
rest	I-I
and	O
60	B-I
min	I-I
of	I-I
exercise	I-I
twice	O
before	O
(	O
45	O
%	O
and	O
65	O
%	O
V	O
(	O
O2	O
peak	O
)	O
)	O
and	O
twice	O
after	O
9	B-I
wk	I-I
of	I-I
endurance	I-I
training	I-I
(	O
55	O
%	O
and	O
65	O
%	O
posttraining	O
V	O
(	O
O2	O
peak	O
)	O
)	O
.	O

Measurements	O
across	O
an	O
exercising	O
leg	O
were	O
taken	O
to	O
be	O
a	O
surrogate	O
for	O
active	B-O
skeletal	I-O
muscle	I-O
.	O

To	O
determine	O
limb	B-O
lipid	I-O
exchange	I-O
,	O
femoral	B-O
arterial	I-O
and	O
venous	B-O
blood	I-O
samples	I-O
drawn	O
simultaneously	O
at	O
rest	O
and	O
during	O
exercise	O
were	O
analyzed	O
for	O
total	B-O
and	O
individual	B-O
FFA	I-O
(	O
e	O
.	O
g	O
.	O
,	O
palmitate	B-O
,	O
oleate	B-O
)	O
,	O
LDL	B-O
-	I-O
C	I-O
,	O
HDL	B-O
-	I-O
C	I-O
,	O
and	O
TG	B-O
concentrations	I-O
,	O
and	O
limb	B-O
blood	I-O
flow	O
was	O
determined	O
by	O
thermodilution	O
.	O

-DOCSTART-	O

Title	O
:	O
Late	O
miscarriage	O
and	O
preterm	O
birth	O
after	O
treatment	O
with	O
clindamycin	B-I
:	O
a	O
randomised	O
consent	O
design	O
study	O
according	O
to	O
Zelen	O
.	O

METHODS	O
:	O
Randomised	O
consent	O
design	O
for	O
clinical	O
trials	O
according	O
to	O
Zelen	O
.	O

Southeast	O
region	O
of	O
Sweden	O
.	O

A	O
total	O
of	O
9025	O
women	O
were	O
screened	O
in	O
early	O
pregnancy	O
.	O

A	B-P
total	I-P
of	I-P
819	I-P
women	I-P
with	I-P
a	I-P
Nugent	I-P
score	I-P
of	I-P
6	I-P
and	I-P
above	I-P
were	I-P
considered	I-P
to	I-P
have	I-P
BV	I-P
and	I-P
treated	I-P
according	I-P
to	I-P
Zelen	I-P
allocation	I-P
.	O

The	B-O
incidence	I-O
of	I-O
late	I-O
miscarriage	I-O
and	O
spontaneous	B-O
(	I-O
noniatrogenic	I-O
)	I-O
preterm	I-O
birth	I-O
was	O
assessed	O
.	O

Late	B-O
miscarriage	I-O
and	O
spontaneous	B-O
preterm	I-O
delivery	I-O
before	O
37	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Confidential	B-I
registration	I-I
in	O
health	O
services	O
:	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Randomised	O
controlled	O
trial	O
.	O

Emergency	O
Department	O
,	O
University	O
Hospital	O
of	O
Wales	O
.	O

A	B-P
total	I-P
of	I-P
302	I-P
patients	I-P
aged	I-P
over	I-P
15	I-P
years	I-P
.	O

Binary	B-O
choices	I-O
and	O
ordinal	B-O
visual	I-O
analogue	I-O
scores	I-O
from	O
a	B-O
validated	I-O
questionnaire	I-O
on	O
self	O
reported	O
measures	O
:	O
patient	B-O
ability	I-O
and	O
preference	B-O
to	I-O
speak	I-O
to	I-O
receptionists	I-O
and	O
disclose	B-O
confidential	I-O
information	I-O
without	I-O
being	I-O
overhead	I-O
and	O
concern	B-O
about	I-O
disclosure	I-O
of	I-O
items	I-O
of	I-O
confidential	I-O
personal	I-O
information	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Neurocognitive	O
outcomes	O
in	O
off	B-I
-	I-I
pump	I-I
versus	O
on	B-I
-	I-I
pump	I-I
bypass	I-I
surgery	I-I
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Consecutively	B-P
listed	I-P
candidates	I-P
for	I-P
elective	I-P
bypass	I-P
were	O
randomly	O
assigned	O
to	O
either	O
off	B-I
-	I-I
pump	I-I
or	O
on	B-I
-	I-I
pump	I-I
techniques	I-I
(	O
n	O
=	O
107	O
)	O
.	O

A	B-O
battery	I-O
of	I-O
11	I-O
standardized	I-O
neuropsychological	I-O
tests	I-O
was	O
administered	O
before	O
surgery	O
,	O
and	O
again	O
at	O
2	O
and	O
6	O
months	O
after	O
surgery	O
.	O

The	O
two	O
groups	O
were	O
compared	O
using	O
a	O
range	O
of	O
statistical	O
procedures	O
,	O
including	O
growth	O
modeling	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Profiles	O
of	O
irregular	O
bleeding	O
induced	O
by	O
low	B-I
-	I-I
dose	I-I
hormone	I-I
therapy	I-I
and	O
Chinese	B-I
formulated	I-I
herbs	I-I
products	I-I
]	O
.	O

METHODS	O
:	O
Applied	O
with	O
open	O
-	O
labeled	O
,	O
randomized	O
,	O
and	O
clinical	O
trial	O
design	O
,	O
136	B-P
postmenopausal	I-P
women	I-P
were	O
assigned	O
into	O
four	O
groups	O
:	O
group	O
A	O
:	O
estradiol	B-I
valerate	I-I
(	I-I
E2	I-I
V	I-I
)	I-I
1	O
mg	O
/	O
d	O
+	O
medroxyprogesterone	B-I
acetate	I-I
(	I-I
MPA	I-I
)	I-I
2	O
mg	O
/	O
d	O
;	O
group	O
B	O
:	O
conjugated	B-I
equine	I-I
estrogen	I-I
0	O
.	O
45	O
mg	O
/	O
d	O
+	O
MPA	B-I
2	O
mg	O
/	O
d	O
;	O
group	O
C	O
:	O
tibolone	B-I
1	O
.	O
25	O
mg	O
/	O
d	O
;	O
group	O
D	O
:	O
a	B-I
Chinese	I-I
formulated	I-I
herbs	I-I
product	I-I
(	I-I
Kuntai	I-I
)	I-I
4	O
#	O
tid	O
.	O

Each	O
subject	O
took	O
element	O
calcium	O
400	O
mg	O
/	O
d	O
and	O
vitamin	O
D	O
200	O
IU	O
/	O
d	O
concomitantly	O
.	O

Modified	B-O
Kupperman	I-O
scores	I-O
were	O
assessed	O
on	O
baseline	O
and	O
every	O
3	O
months	O
thereafter	O
and	O
irregular	B-O
bleeding	I-O
was	O
recorded	O
on	O
menopausal	O
diary	O
every	O
day	O
.	O

The	O
duration	O
of	O
this	O
study	O
was	O
1	O
year	O
.	O

Results	O
The	O
efficacies	O
were	O
similar	O
in	O
three	O
HT	O
-	O
managed	O
groups	O
,	O
but	O
was	O
better	O
than	O
in	O
group	O
D	O
,	O
although	O
the	O
latter	O
was	O
also	O
effective	O
in	O
alleviating	O
menopausal	O
symptoms	O
.	O

Hazard	O
ratio	O
(	O
HR	O
)	O
of	O
irregular	O
bleeding	O
was	O
1	O
.	O
00	O
in	O
group	O
C	O
,	O
2	O
.	O
43	O
in	O
group	O
A	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
08	O
-	O
5	O
.	O

46	O
)	O
,	O
3	O
.	O
12	O
in	O
group	O
B	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
42	O
-	O
6	O
.	O

88	O
)	O
,	O
and	O
0	O
.	O
73	O
in	O
group	O
D	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
26	O
-	O
2	O
.	O
04	O
)	O
.	O

Most	O
cases	O
initially	O
experienced	O
bleeding	O
in	O
the	O
first	O
3	O
months	O
but	O
such	O
initiation	O
was	O
a	O
bit	O
later	O
in	O
group	O
C	O
.	O

Endometrium	O
,	O
as	O
detected	O
by	O
B	O
-	O
mode	O
ultrasound	O
,	O
increased	O
approximately	O
1	O
mm	O
in	O
HT	O
groups	O
,	O
while	O
it	O
was	O
a	O
bit	O
thicker	O
in	O
group	O
C	O
.	O

Long	O
periods	O
in	O
reproductive	O
age	O
and	O
short	O
time	O
since	O
menopause	O
were	O
high	O
risk	O
factors	O
for	O
irregular	O
bleeding	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
clinical	O
trial	O
of	O
clinician	B-I
feedback	I-I
to	O
improve	O
quality	O
of	O
care	O
for	O
inner	B-P
-	I-P
city	I-P
children	I-P
with	I-P
asthma	I-P
.	O

METHODS	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	B-O
effectiveness	I-O
of	O
timely	B-I
patient	I-I
feedback	I-I
in	O
the	O
form	O
of	O
a	O
letter	O
providing	O
recent	O
patient	B-O
-	I-O
specific	I-O
symptoms	I-O
,	O
medication	B-O
,	O
and	O
health	B-O
service	I-O
use	I-O
combined	I-O
with	I-O
guideline	I-O
-	I-O
based	I-O
recommendations	I-O
for	I-O
changes	I-O
in	I-O
therapy	I-O
on	O
improving	O
the	B-O
quality	I-O
of	I-O
asthma	I-O
care	I-O
by	I-O
inner	I-O
-	I-O
city	I-O
primary	I-O
care	I-O
providers	I-O
and	O
on	O
resultant	B-O
asthma	I-O
morbidity	I-O
.	O

This	O
was	O
a	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
in	O
5	B-P
-	I-P
to	I-P
11	I-P
-	I-P
year	I-P
-	I-P
old	I-P
children	I-P
(	I-P
n	I-P
=	I-P
937	I-P
)	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
asthma	I-P
receiving	O
health	O
care	O
in	O
hospital	O
-	O
and	O
community	O
-	O
based	O
clinics	O
and	O
private	O
practices	O
in	O
7	O
inner	O
-	O
city	O
urban	O
areas	O
.	O

The	O
caretaker	O
of	O
each	O
child	O
received	O
a	O
bimonthly	O
telephone	O
call	O
to	O
collect	O
clinical	B-O
information	I-O
about	I-O
the	I-O
child	I-O
'	I-O
s	I-O
asthma	I-O
.	O

For	O
a	O
full	O
year	O
,	O
the	O
providers	O
of	O
intervention	O
group	O
children	O
received	O
bimonthly	B-O
computer	I-O
-	I-O
generated	I-O
letters	I-O
based	O
on	O
these	O
calls	O
summarizing	O
the	B-O
child	I-O
'	I-O
s	I-O
asthma	I-O
symptoms	I-O
,	O
health	B-O
service	I-O
use	I-O
,	O
and	O
medication	B-O
use	I-O
with	O
a	O
corresponding	O
recommendation	O
to	O
step	O
up	O
or	O
step	O
down	O
medications	O
.	O

We	O
measured	O
the	B-O
number	I-O
and	O
proportion	B-O
of	I-O
scheduled	I-O
visits	I-O
resulting	O
in	O
stepping	O
up	O
of	O
medications	O
,	O
asthma	B-O
symptoms	I-O
(	O
2	O
-	O
week	O
recall	O
)	O
,	O
and	O
health	B-O
care	I-O
use	I-O
(	O
2	O
-	O
month	O
recall	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Paraesthesia	O
during	O
the	B-I
needle	I-I
-	I-I
through	I-I
-	I-I
needle	I-I
and	O
the	B-I
double	I-I
segment	I-I
technique	I-I
for	O
combined	O
spinal	O
epidural	O
anaesthesia	O
.	O

METHODS	O
:	O
We	O
randomly	O
allocated	O
116	B-P
parturients	I-P
undergoing	I-P
elective	I-P
Caesarean	I-P
section	I-P
to	O
receive	O
anaesthesia	O
using	O
one	O
of	O
these	O
techniques	O
.	O

Both	O
techniques	O
were	O
performed	O
using	O
a	B-I
27G	I-I
pencil	I-I
point	I-I
needle	I-I
,	O
an	B-I
18G	I-I
Tuohy	I-I
needle	I-I
,	O
and	O
a	B-I
20G	I-I
multiport	I-I
epidural	I-I
catheter	I-I
from	O
the	O
same	O
manufacturer	O
.	O

-DOCSTART-	O

Title	O
:	O
Psychological	O
well	O
-	O
being	O
correlates	O
with	O
free	O
thyroxine	O
but	O
not	O
free	O
3	O
,	O
5	O
,	O
3	O
'	O
-	O
triiodothyronine	O
levels	O
in	O
patients	O
on	O
thyroid	B-I
hormone	I-I
replacement	I-I
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
relationship	O
between	O
psychological	B-O
well	I-O
-	I-O
being	I-O
and	O
free	O
T	O
(	O
4	O
)	O
(	O
fT4	O
)	O
,	O
free	O
T	O
(	O
3	O
)	O
(	O
fT3	O
)	O
,	O
TSH	O
,	O
and	O
total	O
rT	O
(	O
3	O
)	O
in	O
697	B-P
patients	I-P
on	O
thyroid	B-I
hormone	I-I
replacement	I-I
therapy	I-I
at	O
entry	O
to	O
a	O
randomized	O
,	O
controlled	O
trial	O
of	O
combined	B-I
T	I-I
(	I-I
4	I-I
)	I-I
and	O
T	B-I
(	I-I
3	I-I
)	I-I
replacement	I-I
therapy	I-I
.	O

All	O
patients	O
were	O
on	O
100	B-I
mug	I-I
or	O
more	B-I
T	I-I
(	I-I
4	I-I
)	I-I
.	O

Psychological	B-O
well	I-O
-	I-O
being	I-O
was	O
assessed	O
with	O
General	B-O
Health	I-O
Questionnaire	I-O
-	I-O
12	I-O
(	I-O
GHQ	I-O
-	I-O
12	I-O
)	I-O
,	O
Thyroid	B-O
Symptom	I-O
Questionnaire	I-O
,	O
and	O
Hospital	B-O
Anxiety	I-O
and	I-O
Depression	I-O
Scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Specific	B-I
immunoglobulin	I-I
for	O
treatment	O
of	O
whooping	O
cough	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
at	O
three	O
Swedish	O
hospitals	O
.	O

We	O
enrolled	O
73	B-P
children	I-P
aged	I-P
less	I-P
than	I-P
36	I-P
months	I-P
who	I-P
were	I-P
admitted	I-P
with	I-P
a	I-P
clinical	I-P
diagnosis	I-P
of	I-P
whooping	I-P
cough	I-P
.	O

On	O
admission	O
they	O
were	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
(	O
a	O
)	O
monocomponent	B-I
pertussis	I-I
toxoid	I-I
vaccine	I-I
;	O
(	O
b	O
)	O
two	B-I
-	I-I
component	I-I
acellular	I-I
vaccine	I-I
also	I-I
containing	I-I
filamentous	I-I
haemagglutinin	I-I
;	O
or	O
(	O
c	O
)	O
20	B-C
%	I-C
albumin	I-C
solution	I-C
(	O
placebo	B-C
)	O
.	O

The	B-I
immunoglobulins	I-I
had	O
a	O
high	O
antitoxin	O
content	O
and	O
had	O
been	O
raised	O
with	O
acellular	O
pertussis	O
vaccines	O
.	O

-DOCSTART-	O

Title	O
:	O
Teaching	O
young	B-P
nonverbal	I-P
children	I-P
with	I-P
autism	I-P
useful	O
speech	O
:	O
a	O
pilot	O
study	O
of	O
the	O
Denver	O
Model	O
and	O
PROMPT	O
interventions	O
.	O

METHODS	O
:	O
Ten	B-P
young	I-P
,	I-P
nonverbal	I-P
children	I-P
with	I-P
autism	I-P
were	O
matched	O
in	O
pairs	O
and	O
randomized	O
to	O
treatment	O
.	O

They	O
received	O
12	B-I
1	I-I
-	I-I
h	I-I
weekly	I-I
sessions	I-I
of	I-I
therapy	I-I
and	O
daily	B-I
1	I-I
-	I-I
h	I-I
home	I-I
intervention	I-I
delivered	O
by	O
parents	O
.	O

Fidelity	B-O
criteria	I-O
were	O
maintained	O
throughout	O
.	O

-DOCSTART-	O

Title	O
:	O
Gemcitabine	B-I
and	O
split	B-I
-	I-I
dose	I-I
paclitaxel	I-I
or	O
docetaxel	B-I
in	O
metastatic	O
breast	O
cancer	O
:	O
a	O
randomised	O
phase	O
II	O
study	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
210	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
treatment	O
arms	O
:	O
gemcitabine	B-I
1	O
,	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
Days	O
1	O
and	O
8	O
and	O
paclitaxel	B-I
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
3	O
-	O
h	O
infusion	O
on	O
Day	O
1	O
(	O
GP1	O
)	O
;	O
gemcitabine	B-I
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
Days	O
1	O
and	O
8	O
and	O
paclitaxel	B-I
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
1	O
-	O
h	O
infusion	O
on	O
Days	O
1	O
and	O
8	O
(	O
GP2	O
)	O
;	O
gemcitabine	B-I
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
Days	O
1	O
and	O
8	O
and	O
docetaxel	B-I
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
as	O
a	O
1	O
-	O
h	O
infusion	O
on	O
Days	O
1	O
and	O
8	O
(	O
GD	O
)	O
.	O

Cycles	O
were	O
repeated	O
every	O
3	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Divalproex	B-I
versus	O
placebo	B-C
for	O
the	O
prevention	O
of	O
irritability	O
associated	O
with	O
fluoxetine	O
treatment	O
in	O
autism	O
spectrum	O
disorder	O
.	O

-DOCSTART-	O

Title	O
:	O
Enhanced	O
bioavailability	O
of	O
zeaxanthin	B-I
in	O
a	B-I
milk	I-I
-	I-I
based	I-I
formulation	I-I
of	I-I
wolfberry	I-I
(	I-I
Gou	I-I
Qi	I-I
Zi	I-I
;	I-I
Fructus	I-I
barbarum	I-I
L	I-I
.	I-I
)	I-I
.	O

METHODS	O
:	O
The	O
present	O
study	O
investigated	O
zeaxanthin	B-I
bioavailability	B-O
from	O
three	O
wolfberry	O
formulations	O
.	O

Berries	O
were	O
homogenised	O
in	O
hot	O
(	O
80	O
degrees	O
C	O
)	O
water	O
,	O
warm	O
(	O
40	O
degrees	O
C	O
)	O
skimmed	O
milk	O
and	O
hot	O
(	O
80	O
degrees	O
C	O
)	O
skimmed	O
milk	O
,	O
with	O
freeze	O
drying	O
of	O
each	O
preparation	O
into	O
a	O
powdered	O
form	O
.	O

A	B-I
zeaxanthin	I-I
-	I-I
standardised	I-I
dose	I-I
(	O
15	O
mg	O
)	O
of	O
each	O
was	O
consumed	O
,	O
in	O
randomised	O
order	O
,	O
together	O
with	O
a	B-C
standardised	I-C
breakfast	I-C
by	O
twelve	B-P
healthy	I-P
,	I-P
consenting	I-P
subjects	I-P
in	I-P
a	I-P
cross	I-P
-	I-P
over	I-P
trial	I-P
,	I-P
with	I-P
a	I-P
3	I-P
-	I-P
5	I-P
-	I-P
week	I-P
washout	I-P
period	I-P
between	I-P
treatments	I-P
.	O

Blood	B-O
samples	I-O
were	O
taken	O
via	O
a	O
venous	O
cannula	O
immediately	O
before	O
(	O
fasting	O
)	O
and	O
2	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
8	O
and	O
10	O
h	O
post	O
-	O
ingestion	O
.	O

Zeaxanthin	B-O
concentration	I-O
in	I-O
the	I-O
triacylglycerol	I-O
-	I-O
rich	I-O
lipoprotein	I-O
fraction	I-O
of	I-O
plasma	I-O
was	O
measured	O
by	O
HPLC	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
zoledronic	B-I
acid	I-I
in	O
patients	B-P
with	I-P
breast	I-P
cancer	I-P
metastatic	I-P
to	I-P
bone	I-P
:	O
a	O
multicenter	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Patients	B-P
diagnosed	I-P
with	I-P
bone	I-P
metastases	I-P
<	I-P
or	I-P
=	I-P
6	I-P
weeks	I-P
prior	I-P
to	I-P
first	I-P
visit	I-P
were	O
enrolled	O
.	O

Zoledronic	B-I
acid	I-I
(	O
4	O
mg	O
)	O
was	O
administered	O
via	O
a	O
15	O
-	O
minute	O
infusion	O
every	O
3	O
or	O
4	O
weeks	O
for	O
12	O
infusions	O
.	O

Skeletal	B-O
-	I-O
related	I-O
events	I-O
(	I-O
SREs	I-O
)	I-O
were	O
defined	O
as	O
pathologic	B-O
bone	I-O
fractures	I-O
,	O
spinal	B-O
cord	I-O
compression	I-O
,	O
surgery	B-O
to	I-O
bone	I-O
,	O
radiation	B-O
therapy	I-O
to	I-O
bone	I-O
,	O
and	O
hypercalcemia	B-O
of	I-O
malignancy	I-O
.	O

Primary	O
efficacy	O
end	O
points	O
were	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
at	I-O
least	I-O
one	I-O
SRE	I-O
and	O
the	B-O
time	I-O
to	I-O
first	I-O
SRE	I-O
.	O

Secondary	O
end	O
points	O
included	O
pain	B-O
,	O
analgesic	B-O
use	I-O
,	O
and	O
quality	B-O
of	I-O
life	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Control	O
of	O
the	O
lumbar	O
neutral	O
zone	O
decreases	O
low	O
back	O
pain	O
and	O
improves	O
self	O
-	O
evaluated	O
work	O
ability	O
:	O
a	O
12	O
-	O
month	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
study	O
with	O
12	O
months	O
intervention	O
.	O

METHODS	O
:	O
Middle	B-P
-	I-P
aged	I-P
working	I-P
men	I-P
with	I-P
recent	I-P
LBP	I-P
but	I-P
without	I-P
severe	I-P
disability	I-P
were	O
randomly	O
allocated	O
to	O
either	O
a	B-I
training	I-I
(	O
TG	O
,	O
n	O
=	O
52	O
)	O
or	O
control	O
group	O
(	O
CG	O
,	O
n	O
=	O
54	O
)	O
.	O

The	O
aim	O
was	O
to	O
exercise	B-I
twice	O
a	O
week	O
for	O
12	O
months	O
,	O
once	O
guided	O
and	O
once	O
independently	O
.	O

The	O
outcome	O
measures	O
were	O
the	O
changes	O
in	O
intensity	B-O
of	I-O
LBP	I-O
,	O
disability	B-O
,	O
self	B-O
-	I-O
evaluated	I-O
future	I-O
work	I-O
ability	I-O
,	O
and	O
neuromuscular	B-O
fitness	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Rationale	O
and	O
design	O
of	O
the	B-I
Folic	I-I
Acid	I-I
for	O
Vascular	O
Outcome	O
Reduction	O
In	O
Transplantation	O
(	O
FAVORIT	O
)	O
trial	O
.	O

METHODS	O
:	O
FAVORIT	O
is	O
a	O
multicenter	O
double	O
-	O
blind	O
randomized	O
controlled	O
clinical	O
trial	O
.	O

Participants	B-P
are	I-P
clinically	I-P
stable	I-P
renal	I-P
transplant	I-P
recipients	I-P
who	I-P
are	I-P
6	I-P
months	I-P
or	I-P
longer	I-P
posttransplant	I-P
with	I-P
elevated	I-P
tHcy	I-P
.	O

Patients	O
are	O
randomized	O
to	O
a	B-I
multivitamin	I-I
that	O
includes	O
either	O
a	B-I
high	I-I
-	I-I
dose	I-I
or	O
low	B-I
-	I-I
dose	I-I
of	I-I
folic	I-I
acid	I-I
(	O
5	O
or	O
0	O
mg	O
)	O
,	O
vitamin	B-I
B6	I-I
(	O
50	O
or	O
1	O
.	O
4	O
mg	O
)	O
,	O
and	O
vitamin	B-I
B12	I-I
(	O
1000	O
or	O
2	O
microg	O
)	O
.	O

The	O
primary	O
end	O
point	O
is	O
a	O
composite	O
of	O
incident	B-O
or	O
recurrent	B-O
CVD	I-O
outcomes	I-O
,	O
that	O
is	O
,	O
coronary	B-O
heart	I-O
,	O
cerebrovascular	B-O
,	O
or	O
abdominal	B-O
aortic	I-O
/	I-O
lower	I-O
extremity	I-O
arterial	I-O
events	I-O
.	O

A	O
sample	O
size	O
of	O
4000	O
is	O
estimated	O
to	O
provide	O
87	O
%	O
power	O
to	O
detect	O
a	O
20	O
%	O
treatment	O
effect	O
.	O

Recruitment	O
is	O
expected	O
to	O
continue	O
until	O
July	O
2006	O
,	O
with	O
follow	O
-	O
up	O
through	O
June	O
2010	O
.	O

